Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Novartis
Mallinckrodt
Dow
Medtronic
QuintilesIMS
Federal Trade Commission
McKinsey
Chubb
McKesson

Generated: December 10, 2017

DrugPatentWatch Database Preview

PHOTREXA VISCOUS IN DEXTRAN 20% Drug Profile

« Back to Dashboard

When do Photrexa Viscous In Dextran 20% patents expire, and what generic alternatives are available?

Photrexa Viscous In Dextran 20% is a drug marketed by Avedro Inc and is included in one NDA.

The generic ingredient in PHOTREXA VISCOUS IN DEXTRAN 20% is riboflavin 5'-phosphate sodium. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the riboflavin 5'-phosphate sodium profile page.

Summary for PHOTREXA VISCOUS IN DEXTRAN 20%

You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM') AND hsdb_drugname IS NOT NULL' at line 1
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 30
Clinical Trials: 82